ESPE Abstracts

Introduction: The complex interplay between nutritional status, body mass index (BMI), and insulin-like growth factor-1 (IGF-1) is pivotal in understanding pediatric growth. Our study investigates these relationships to enhance growth outcomes in children.Objective: We aimed to evaluate the effects of nutritional interventions on BMI, height growth velocity, and IGF-1 levels in 125 underweight children aged 2-10, who und...

Background: The growth and development of human tissues are critically regulated by the Insulin-like Growth Factor 1 Receptor (IGF1R) and its ligand IGF-1. Mutations in the IGF1R gene and less frequently in the IGF1 gene are associated with a heterogeneous group of growth disorders, manifesting as intrauterine and postnatal growth retardation.Literature Review: In this review, 30 published papers were analyzed, giving a ...

Introduction: Children born small for gestational age (SGA) are susceptible to abnormal glucose metabolism and insulin resistance, which may be exacerbated by (GH) therapy.Methods: A comprehensive analysis of existing literature was conducted to assess the outcomes and implications of GH treatment in this specific pediatric population.Results: 10 studies were reviewed, (1458 SGA ch...

Background: The infantile growth parameters of children diagnosed later in life with GH-deficiency is still very controversial.Methods: We synthesized data from eight key studies, spanning from 1984 to 2003, alongside our current patient data. The LSDS and WtSDS at birth, 2 months, and 24 months are compared, noting the presence or absence of significant growth retardation or deviation from expected growth standards....

Introduction: Growth Hormone Deficiency (GHD) is a critical condition that impairs the normal growth patterns in children, leading to various health challenges. Previous studies, including that by Leger et al. (1996), have characterized the secretion curve of growth hormone (GH) in early childhood. Our study aims to link the timed infantile growth data, specifically Length and Weight Standard Deviation Scores (LSDS and WTSDS), of children with diagnos...

Background: The precise growth hormone (GH) cut-off value for diagnosing growth hormone deficiency (GHD) in children is a subject of ongoing debate. With GH provocative tests typically using cut-offs between 4.7 and 6.5 µg/L, the traditional threshold of <10 µg/L is being reconsidered in favor of <7 µg/L due to advancements in GH assay standardization. Magnetic resonance imaging (MRI) of the pituitary gland is a crucial diagnostic tool,...

Introduction: Glucagon serves as a growth hormone (GH) secretagogue. Serial measurements of GH concentration following glucagon administration are one of the growth hormone stimulation tests (GHSTs) for assessing GH sufficiency in children with suspected growth hormone deficiency (GHD). Although intramuscular glucagon is utilized to evaluate GH secretion, the relationship between changes in blood glucose (BG) and GH during this test has not been thoroughly stu...

There is still controversy about body composition after completion of growth hormone (GH) therapy in patients with GHD once final adult height has been reached.Objective: A cross-sectional study was conducted to evaluate body composition in males after GH therapy discontinuation, during the transition stage.Patients and Methods: 18 males with confirmation of persistent GHD (16.7-21.5 years) after G...

Objective: Very small embryonic/epiblast&dash;like stem cells (VSELs), found in human bone marrow and other adult tissues, also in circulating blood are small, non-hematopoietic cells expressing markers of pluripotent embryonic and primordial germ cells. VSELs are responsible for postnatal tissue and organ rejuvenation. It was reported that VSELs decreased after prolonged GH or IGF-1 administration in experimental animals and after prolonged IGF-1 administrati...

Somapacitan is currently the only long-acting GH approved by FDA, PDMA and EMA to treat GH deficiency (GHD) in both children and adults. Similar efficacy, safety, and tolerability in children with GHD was demonstrated for somapacitan (0.16 mg/kg/week) compared to daily GH (0.034 mg/kg/day) in the global phase 3 REAL4 study, which was conducted in 20 countries within Asia (excluding China), Europe, and North America. Efficacy and safety of somapacitan in Chinese children with G...

Objective: To understand whether characterization into definite growth hormone deficiency (dGHD; peak GH <8 ug/L and identifiable genetic, functional or anatomical cause), short stature unresponsive to stimulation test (SUS; peak GH <8 ug/L but without any identifiable cause) or idiopathic short stature (ISS; peak GH ≥8) can predict the near adult height (NAH) of prepubertal children treated with recombinant human growth hormone (rhGH).<p class="a...